Showing 1871-1880 of 2038 results for "".
- Health Care Experts Named to Biden’s COVID-19 Advisory Boardhttps://modernod.com/news/health-care-experts-named-to-bidens-covid-19-advisory-board/2478511/Former U.S. Surgeon General Vivek Murthy, MD, and former FDA Commissioner David Kessler, MD, will be among the public health leaders guiding the transition team for President-elect Joe Biden regarding COVID-19, according to a FierceHealthcare
- Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039https://modernod.com/news/nicox-granted-new-patent-for-ncx-470-extending-exclusivity-in-europe-to-2039/2478471/Nicox announced that the European Patent Office has granted a formulation patent for NCX 470, extending the European exclusivity to 2039. The equivalent U.S. patent has already been granted, and NCX 470 is also covered by granted composition of matter patents. “We are pleased that our form
- Katena Products Acquires Micro-Select Instrumentshttps://modernod.com/news/katena-products-acquires-micro-select-instruments/2478435/Katena Products announced the purchase of Micro-Select Instruments, a maker of ophthalmic instruments including forceps, needle holders, and speculums. Terms of the deal were not disclosed. “The acquisition of Micro-Select is an important addition to Katena’s growing instrument manu
- Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatmenthttps://modernod.com/news/oxular-receives-rare-paediatric-disease-and-orphan-drug-designations-for-retinoblastoma-treatment/2478404/Oxular Limited announces it has received both rare paediatric disease and orphan drug designations from the FDA for OXU-003, the company’s proprietary drug in development for the treatment of retinoblastoma. Retinoblastoma is a rare form of eye cancer that usually develops in early childho
- Bausch Health Licenses Eyenovia’s Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12https://modernod.com/news/bausch-health-licenses-eyenovias-investigational-treatment-for-the-reduction-of-pediatric-myopia-progression-in-children-ages-3-12/2478405/Bausch Health Companies and Eyenovia announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulati
- ProQR Announces Virtual Presentations at Euretina and AAOpthttps://modernod.com/news/proqr-announces-virtual-presentations-at-euretina-and-aaopt/2478348/ProQR Therapeutics announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt). ProQR’s presentation at Ophthalmology Futures Retina Forum</
- Visus Therapeutics Launches and Announces Clinical Development Program for Novel Presbyopia Eye Drophttps://modernod.com/news/visus-therapeutics-launches-and-announces-clinical-development-program-for-novel-presbyopia-eye-drop/2478333/Visus Therapeutics announced its launch and clinical development program for a novel eye drop designed to restore the loss of near vision associated with presbyopia. Visus’ lead product candidate is Brimochol, a proprietary formulation that combines two FDA-approved pharmaceuticals: carbachol and
- Trump Signs Executive Orders on Preexisting Condition Protections, Surprise Billinghttps://modernod.com/news/trump-signs-executive-orders-on-preexisting-condition-protections-surprise-billing/2478328/President Donald Trump signed an executive order that declares it a national policy to protect patients with preexisting conditions regardless of the fate of the Affordable Care Act (ACA)—but just how they’ll force insurers to comply remains unclear, according to a FierceHealthcare
- FDA Approves Bausch + Lomb Alaway Preservative Free OTC Dropshttps://modernod.com/news/fda-approves-bausch-lomb-alaway-preservative-free-ophthalmic-solution/2478329/Bausch + Lomb and Eton Pharmaceuticals announced that the FDA has approved Alaway Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100), as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy
- Optimo Medical Gets Support by Innosuisse to Enter the US Markethttps://modernod.com/news/optimo-medical-gets-support-by-innosuisse-to-enter-the-us-market/2478322/Optimo Medical announced that Optimeyes is ready to enter the US market after the FDA decided not to enforce any regulatory requirements, known as enforcement discretion. This important step forward opened the doors for Optimo Medical to receive the additional boost of a Swissnex bootcamp